An intravenous monoclonal antibody (passive immunotherapy) for the treatment of patients with mild early-stage Alzheimer’s disease.
Emerging Technology Reports
The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.
For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.
Cometriq (Cabozantinib)
An oral agent for the treatment of progressive unresectable or metastatic medullary thyroid cancer.
Trevo® Pro / Trevo® ProVue™ Retrieval System
A microcatheter with an integrated stent-like retriever device for revascularization in patients with acute ischemic stroke who are ineligible for or who fail intravenous tissue plasminogen activator therapy.
Zilver® PTX® Paclitaxel-Eluting Peripheral Arterial Stent
A polymer-free, paclitaxel-eluting, self-expanding nitinol stent for treatment of de novo and restenotic lesions up to 140 mm long in patients with symptomatic femoropopliteal peripheral artery disease above the knee.
Absorb™ Bioresorbable Vascular Scaffold (BVS)
A fully bioabsorbable, everolimus-eluting, coronary artery stent designed to eliminate the need for long-term antiplatelet therapy.
somo•v® Automated Breast Ultrasound System
An automated, whole-breast, three-dimensional ultrasound scanning system for breast cancer screening in patients with dense breasts, used as an adjunct to x-ray mammography.
Xeljanz® (Tofacitinib)
An oral Janus kinase inhibitor for the treatment of moderate to severe rheumatoid arthritis.
Xarelto® (Rivaroxaban) for Treatment of Acute Venous Thromboembolism (VTE) and VTE Secondary Prevention
An oral factor Xa direct inhibitor for the treatment of acute venous thromboembolism (VTE) and prevention of VTE recurrence.
Stivarga® (Regorafenib) for Metastatic Colorectal Cancer
Oral multikinase inhibitor for the third-line treatment of chemorefractory metastatic colorectal cancer.
Genous™ Bio-Engineered R Stent
A coronary artery stent coated with anti-CD34 antibodies, designed to obviate the need for prolonged antiplatelet therapy after implantation.